Lv3
348 积分 2023-06-19 加入
ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024)
4小时前
待确认
[Introduction and interpretation of the updated contents of the International System for Human Cytogenomic Nomenclature]
4小时前
已完结
The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH)
5小时前
已完结
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
14天前
已完结
Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia
15天前
已完结
Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia
15天前
已完结
Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study
16天前
已完结
Targeted therapy in acute myeloid leukemia: resistance and overcoming strategy
1个月前
已完结
Glasdigib fails to slay the hedgehog in pivotal AML trials
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
皖公网安备34019202002308
